Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center

References

• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714.
   PubMed Web of Science ®Google Scholar
• Spicknall KE. Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):18–23.
   PubMed Web of Science ®Google Scholar
• Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011–1019.
   PubMed Web of Science ®Google Scholar
• da Silva Almeida AC, Abate F, Khiabanian H, et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet. 2015;47(12):1465–1470.
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–771.
   PubMed Web of Science ®Google Scholar
• Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051–5060.
   PubMed Web of Science ®Google Scholar
• Kubica AW, Davis MD, Weaver AL, et al. Sézary syndrome: a study of 176 patients at mayo clinic. J Am Acad Dermatol. 2012;67(6):1189–1199.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–3773.
   PubMed Web of Science ®Google Scholar
• Van-de-Velde V, Zhou Y. Existing and emerging therapies for cutaneous T-cell lymphoma. J Cutan Med Surg. 2019;23(3):319–327.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Hodak E, Bagot M, et al. Blood classification and blood response criteria in mycosis fungoides and sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018;93:47–56.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC). Blood. 2007;110(6):1713–1722.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–2607.
   PubMed Web of Science ®Google Scholar
• Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81.
   PubMed Web of Science ®Google Scholar
• Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006;142(5):577–584.
   PubMedGoogle Scholar
• Shea-Budgell MA, Kostaras X, Myhill KP, et al. Information needs and sources of information for patients during cancer follow-up. Curr Oncol. 2014;21(4):165–173.
   PubMed Web of Science ®Google Scholar
• Pielop JA, Brownell I, Duvic M. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Int J Dermatol. 2003;42(2):116–122.
   PubMed Web of Science ®Google Scholar
• Mangold AR, Thompson AK, Davis MD, et al. Early clinical manifestations of Sézary syndrome: a multicenter retrospective cohort study. J Am Acad Dermatol. 2017;77(4):719–727.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739.
   PubMed Web of Science ®Google Scholar
• Liu X, Loughran TP Jr. The spectrum of large granular lymphocyte leukemia and felty's syndrome. Curr Opin Hematol. 2011;18:254–259.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hussaini M, Brassell D, et al. Understanding circulating large granular lymphocytic proliferations in cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:S273.
   Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2017;28(10):2517–2525.
   PubMed Web of Science ®Google Scholar
• Gao C, McCormack C, van der Weyden C, et al. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with sezary syndrome. Blood. 2019;134(16):1346–1350.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42(8):1014–1030.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2019;30(3):494.
   PubMed Web of Science ®Google Scholar